This Is MS Multiple Sclerosis Community: Knowledge & Support

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
It is currently Thu May 23, 2013 8:09 am


All times are UTC - 8 hours [ DST ]




Post new topic Reply to topic  [ 1 post ] 
Author Message
PostPosted: Thu Apr 13, 2006 6:48 pm 
Offline
Family Elder
User avatar

Joined: Sat Feb 18, 2006 4:00 pm
Posts: 516
Location: suburb of Chicago, IL USA
Not sure if this was a big concern for those of you on Betaseron, but here's some new info


Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.

Baum K; Mannitol Formulation Study Group.

Hennigsdorf Hospital, Free University, Berlin, Germany. k.baum1@gmx.de

The original glucose-based formulation of Betaferon/Betaseron (interferon beta-1b) requires refrigerated storage. A refrigeration-free formulation of interferon beta-1b, based on mannitol, is stable at room temperature for up to 2 years, and offers a greater degree of flexibility for patients with multiple sclerosis (MS). We compared the safety and tolerability of the two formulations in a 24-week, randomized, double-blind, parallel group, Phase IV clinical study conducted in 303 patients with MS. Patients received the glucose formulation (IFNbeta-1b-G) for 8 weeks, and were then randomized to receive either IFNbeta-1b-G or the refrigeration-free formulation (IFNbeta-1b-M) for a further 8 weeks. On completion of the double-blind phase, all patients received IFNbeta-1b-M for an 8-week follow-up period. The primary outcome measure was the proportion of injection sites that developed reactions per patient during the double-blind period. In addition, a range of secondary outcomes relating to these reactions was also assessed. The difference in the proportion of injection-site reactions between the two groups was not statistically significant (59% IFNbeta-1b-G versus 60% IFNbeta-1b-M). There were no statistically significant differences observed between the two treatment groups in any of the secondary tolerability endpoints. The results from this study demonstrate that the tolerability and safety profiles of both formulations are extremely good, and that the refrigeration-free formulation of interferon beta-1b is comparable with that of the original glucose formulation.


Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 1 post ] 

All times are UTC - 8 hours [ DST ]


Related topics
 Topics   Author   Replies   Views   Last post 
There are no new unread posts for this topic. why betaseron?

ga_kristy

3

4163

Tue Oct 18, 2005 5:14 am

JFH View the latest post

There are no new unread posts for this topic. Betaseron user.

Niko

0

2672

Mon Jan 12, 2004 7:20 am

Niko View the latest post

There are no new unread posts for this topic. Started betaseron

cdaw

0

2938

Sun Feb 06, 2005 1:18 pm

cdaw View the latest post

There are no new unread posts for this topic. Starting Betaseron

DeeDee

10

6843

Tue Apr 07, 2009 9:42 am

lesley823 View the latest post

There are no new unread posts for this topic. Generic Betaseron?

2gentle

0

2596

Mon Sep 17, 2007 8:40 pm

2gentle View the latest post

 


Who is online

Users browsing this forum: No registered users


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum

Search for:
Jump to: